Antengene-B (06996): Liu Ying and Lin Qianxi have been appointed as Joint Company Secretaries of the company.

Tecentriq Pharma-B (06996) announced that Mr. Yang Cao and Mr. Weichao Huang have resigned as the Company’s Joint Company Secretaries, effective June 10, 2026. Mr. Yang Cao will continue to serve as Vice President of the Group and oversee capital markets activities. Ms. Ying Liu and Ms. Qianxi Lin have been appointed as the Company’s Joint Company Secretaries to succeed Mr. Cao and Mr. Huang, also effective June 10, 2026.

Zhitong FinanceJun 10 19:19

Antengene Shareholders Back All AGM Resolutions, Bolstering Capital Flexibility

TipRanksJun 10 19:15

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

PR NewswireJun 10 09:00

HKEX Announcement Insights | China Software International: Signs RMB 1 billion high-end AI computing equipment sales agreement to accelerate commercialization of computing power business

China Software International: Signed a RMB 1 billion sales agreement for high-end AI computing equipment to accelerate the commercialization of its computing power business; XtalPi Holdings entered into a strategic AI drug discovery partnership exceeding USD 400 million with a globally renowned pharmaceutical company to develop novel oral drugs targeting GPCRs…

Zhitong FinanceJun 10 08:59

Antengene-B (06996): IND for ATG-201 (CD19×CD3 TCE) for the treatment of autoimmune diseases approved in China

Antengene Corporation-B (06996) announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for ATG-201, a CD19/CD3 bispecific T-cell engager antibody for the treatment of B-cell-mediated autoimmune diseases, to proceed with a Phase I clinical study. Antengene plans to promptly initiate and advance the Phase I study in China and is also preparing for the clinical development of ATG-201 in Australia.

Zhitong FinanceJun 10 06:21

Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

PR NewswireJun 8 08:00